Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial
Latest Information Update: 16 Dec 2025
At a glance
- Drugs HDM 1005 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 16 Dec 2025 New trial record